Senzime AB (publ) (SNZZF) Q2 2026 Earnings Call Prepared Remarks Transcript

Senzime reported a 15% decrease in operating expenses alongside a 27% improvement in EBITDA and a 46% improvement in cash flow, despite essentially flat (0%) revenue growth in the quarter. The company highlighted continued strong growth in sensor utilization but ongoing U.S. headwinds for new monitor sales, with some improvement over the last six months. Management also emphasized a newly announced strategic partnership with Philips, positioning it as the most important commercial agreement to date.

Analysis

The market should separate operating cleanup from real fundamental inflection. Cost cuts and better cash conversion are supportive, but without a sustained re-acceleration in capital sales they mostly improve survival odds and optionality, not intrinsic value. The more important mechanism is recurring sensor utilization: if that keeps compounding, the business shifts toward a higher-quality consumables model with better visibility and a lower cost of capital.

The strategic partnership is meaningful mainly as a distribution and validation event, not as near-term earnings power. The second-order read is that a large OEM now has incentive to push a niche technology into an installed base it already owns, which could reduce customer acquisition costs and force slower-moving competitors to respond on product roadmaps. But these deals often take multiple quarters to convert into measured revenue, so the headline can outrun the P&L.

Risk is mostly timing risk over the next 1-3 quarters: U.S. capital spending can remain soft longer than bulls expect, and the cash-flow improvement can be flattered by working-capital timing. The thesis is falsified if sequential sensor growth stalls again or if there is no concrete commercialization milestone from the OEM relationship within 6-12 months. On a 6-18 month view, the stock only deserves a structural re-rate if recurring revenue becomes the dominant growth engine rather than a support beam.

Key Decisions for Investors

• Start with a small long SNZZF position only on post-call weakness, sized as an optionality trade rather than a core fundamental long; the upside is a multi-quarter re-rate if recurring sensors and OEM distribution compound, but liquidity and execution risk argue for patience.
• Do not chase a headline gap higher in SNZZF; use any 10-15% post-announcement move to trim or fade if the next filing does not show sequential order improvement, since the current P&L trajectory does not yet justify a growth multiple.
• Set a 1-2 quarter alert on SNZZF for three items: sequential sensor utilization, U.S. monitor bookings, and cash conversion versus EBITDA; only add aggressively if all three improve together.
• If available to trade efficiently, consider a hedged expression: long SNZZF against a broader medtech basket to isolate the company-specific commercialization option while reducing market beta, because the main upside driver is not sector-wide.